The outcome for refractory childhood acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (SCT) is usually fatal, and novel therapeutic agents are needed to change this dismal prognosis. Identification of the genes and biological pathways responsible for chemoresistance is therefore crucial for the design of novel therapeutic approaches. 1 DNA methylation is a common epigenetic modification that induces changes in gene expression and hypermethylation, and silencing of key regulatory genes, such as tumour suppressor genes, has been implicated in the biology of ALL and is an independent factor of poor prognosis. DNA methyltransferase inhibitors can reverse these epigenetic mutations. 2 
5-aza-2
0 -deoxyazacytidine (decitabine) is a cytosine analogue that traps all DNA methyltransferases and targets them for degradation. Decitabine induces hypomethylation, thereby promoting cell differentiation, re-expression of tumour suppressor genes, stimulation of immune mechanisms and suppression of tumour growth. 2 This drug has shown clinical activity mostly in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia. However, although in vitro tests have shown that demethylating agents can induce apoptosis of ALL cells, the clinical use of decitabine have not been reported so far in this leukemia. We present the first and successful induction therapy in a patient with refractory ALL.
A 10-year-old white girl was diagnosed in February 2000 (when she was 4 years old) of common B-cell ALL. Initial common B-cell was WBC 18.400 Â 10 9 /l (85% blasts), haemoglobin 7.8 g per 100 ml and platelets 15.000 Â 10 9 /l. Leukaemic blasts immunophenotype was CD19 þ , TdT þ , CD10 þ , CD20 þ low and CD7.1 negative with absence of T-cell or myeloid marker. Structural karyotype was normal. ALL was negative for BCR-ABL or TEL-AML1 translocations, and MLL rearrangements in molecular studies. ALL was classified into standard risk, and treated with the Spanish protocol for ALL Spanish Hemato-Oncology Pediatric Group (SHOP-99), which includes induction therapy with vincristine, prednisone, daunomycin, L-asparaginase and cyclophosphamide, followed by high-dose methotrexate and high-dose cytarabine as consolidation and maintenance therapies for 2 years with i.m. methotrexathe and oral mercaptopurine.
One year after the end of therapy, bone marrow (BM) relapse occurs, and she was treated with the same previous schedule of induction and consolidation therapy. In second complete remission (CR), she underwent autologous peripheral blood SCT (PBSCT) conditioned with total body irradiation (10 Gy) and cyclophosphamide. In May 2006, a second BM relapse occurs, and she was treated again with the same drugs in low doses, achieving a third CR. Response was consolidated with an allogeneic haploidentical PBSCT from her mother conditioned with fludarabine, i.v. busulfan and antithymocyte globulin. She never developed graft-versus-host disease.
A third relapse with massive BM infiltration appeared in January 2008. Flow cytometry, cytogenetic and molecular studies did not show changes in leukemic blasts. Clofarabine alone, and later high-doses of cytarabine associated with rituximab and dexamethasone failed in achieving a new remission. We decided to treat her with decitabine as a compassionate mode after obtaining an informed consent from parents. Doses administered were similar to that used in MDS and AML (15 . Acyclovir, trimethoprim-sulfamethoxazole and cefuroxime were used as antimicrobial prophylaxis. Granulocyte colony-stimulating factor 5 mg/kg was started in day þ 5 to accelerate neutrophil recovery. Complete blood counts were carried out daily, and supportive transfusion was administered when was needed. She developed severe myelosupression and febrile neutropenia that was treated with broad-spectrum agents and antifungal therapy. Neutrophil recovery was achieved in day þ 27, and BM aspiration and biopsy showed CR by cytological and cytometric analyses. She underwent again a second allogeneic PBSCT from her mother, conditioned with fludarabine, i.v. busulfan and total body irradiation (4 Gy). Cyclosporine alone was used for graft-versus-host disease prophylaxis. She recovered normal counts of neutrophils, red blood cells and platelets during the first month after transplantation. At this time, she has developed an extensive chronic graftversus-host disease and continues in CR 8 months after PBSCT. The prognosis for childhood ALL has improved consistently over the past three decades, and now more than 80% of children can be cured with chemotherapy treatment alone. However, some children still die of relapsed or refractory ALL. In general, treatment for the first relapse includes intensive chemotherapy followed by hematopoietic SCT. 3 In patients with second and third relapses or refractory disease, overall survival is below 10%. 4 In these cases, therapeutic options are limited. If relapse occurs after allogeneic SCT, donor lymphocyte infusions can be used, but the success rate observed is lower than in chronic myeloid leukemia. In the last years, clofarabine and nelarabine, new purine analogues, have shown efficacy in relapsed or refractory ALL achieving 40% of overall responses. Other options under investigation are monoclonal antibodies, such as anti-CD22 (Epratuzumab) or anti-CD52 (Campath).
Advances in ALL biology understanding have shown different mechanisms associated with poor prognosis. Several groups have shown how differences in methylation phenotype are associated with distinct clinical and genetic profiles in ALL. Hypomethylation is shown to be associated with chromosomal breaks and lead to an increased cancer incidence in specific animal models. In parallel, hypermethylation of promoters is linked to silencing of gene expression and loss of protein function. 2 Genes that are known to be abnormally hypermethylated in ALL are calcitonin, ER, p15, p16, HIC-1, p73, E-cadherin, promoter-associated CpG islands, Wnt and Src among others. [5] [6] [7] In proliferating cells, DNA methylation is critically dependent on continued expression of DNA methyltransferases. Moreover, several groups have recently shown that aberrant DNA methylation is an independent prognostic factor for disease-free survival, overall survival and treatment resistance. 8, 9 The cytosine analogue 5-aza-2 0 -deoxyazacytidine 2 0 -deoxy-5-azacytidine (decitabine) is an S-phase-specific inhibitor of DNA methyltransferase with a hypomethylating activity. Depending on dose, this drug has a dual mechanism. At higher doses, decitabine inhibits cell proliferation through nonreversible covalent linking with DNA methyltransferase and blocking of DNA synthesis. At lower doses, decitabine induces hypomethylation, thereby promoting cell differentiation, reexpression of tumour suppressor genes, stimulation of immune mechanisms and suppression of tumour growth.
In myeloid malignancies, decitabine have shown efficacy in clinical practice in the treatment of MDS and AML. In fact, the US Food and Drug Administration (FDA) has approved decitabine for the treatment of patients with previously treated, untreated, de novo and secondary MDS, including chronic myelomonocytic leukemia.
In contrast, although in vitro studies in ALL cells have shown that these drugs can reactivate gene expression and restore the normal protein levels, to our knowledge, there is not clinical experience reported so far. The present case is the first clinical evidence about the usefulness of decitabine to treat refractory ALL. Likewise, our experience has shown that decitabine can be used in paediatric patients and is able to induce CR in heavily pretreated patients with acceptable side effects allowing a rapid accomplishment of BM transplantation. All this suggests that this drug should be investigated in refractory ALL. L Yánez, A Bermú dez, C Richard, E Bureo and A Iriondo Hematology Department, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain E-mail: lucrecia@humv.es
